Ardelyx, Inc. News Releases http://ir.ardelyx.com/ Ardelyx, Inc. News Releases en Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-appoints-renowned-nephrologist-geoffrey-block-md-its FREMONT, Calif. , March 14, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), today announced the appointment of Geoffrey A. Block , M.D., Vice President, Nephrology at Reata and former Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver Thu, 14 Mar 2019 17:00:00 -0400 Ardelyx, Inc. News Releases 9471 Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-peer-reviewed-publication-positive-phase-3 - Ardelyx's investigative agent for end-stage renal disease patients on dialysis represents first non-binder innovation to lower patients' phosphate levels, a critically important parameter that is correlated with morbidity and mortality - Ardelyx's approach leverages newly discovered pathway for Thu, 07 Mar 2019 17:00:00 -0500 Ardelyx, Inc. News Releases 9461 Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-fourth-quarter-2018-financial-results-and-recent Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal Wed, 06 Mar 2019 16:05:00 -0500 Ardelyx, Inc. News Releases 9446 Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-participate-leerink-partners-8th-annual-global FREMONT, Calif. , Feb. 21, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb. Thu, 21 Feb 2019 08:00:00 -0500 Ardelyx, Inc. News Releases 9431 Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-collaboration-partner-kyowa-hakko-kirin-announces Ardelyx to Receive a $5 Million Milestone Payment Company Narrows Timeline for its PHREEDOM trial and announces AMPLIFY, a new Phase 3 Trial evaluating tenapanor in combination with binders FREMONT, Calif. , Feb. 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) ( Ardelyx ) today announced that Thu, 07 Feb 2019 06:30:00 -0500 Ardelyx, Inc. News Releases 9406 Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-fda-acceptance-filing-its-new-drug-application FREMONT, Calif. , Nov. 13, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that  the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation Tue, 13 Nov 2018 08:30:00 -0500 Ardelyx, Inc. News Releases 9326 Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2018-financial-results-and-recent Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018 . Wed, 07 Nov 2018 16:05:00 -0500 Ardelyx, Inc. News Releases 9311 Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-presents-new-preclinical-data-demonstrating-synergy Company Plans to Commence a Phase 2/3 Clinical Study Evaluating Tenapanor in Combination with Phosphate Binders FREMONT, Calif. , Oct. 26, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in Fri, 26 Oct 2018 13:01:00 -0400 Ardelyx, Inc. News Releases 9306 Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-showcases-new-data-t3mpo-3-long-term-safety-trial FREMONT, Calif. , Oct. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology Mon, 08 Oct 2018 08:01:00 -0400 Ardelyx, Inc. News Releases 9301 Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-host-its-first-annual-investor-day-focused-treatment FREMONT, Calif. , Oct. 4, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018 , from 8 to 10 a.m. ET in New York City . This year's event is the first of an anticipated annual series of events, and will Thu, 04 Oct 2018 06:30:00 -0400 Ardelyx, Inc. News Releases 9291